The 63rd American Society of Hematology (ASH) annual meeting saw a plethora of updates in lymphoma. While most of them generated a lot of fruitful conversations, some of the breakthroughs have the potential to change practice.
In this roundtable discussion, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, review the most exciting updates in lymphoma from the 2021 ASH annual meeting and reflect on how the data may impact clinical practice in the UK.
EHA 2021: fixed-duration therapies and sequencing in CLL
The AML Sessions: highlights from ASCO/EHA 2021
EHA 2021: key trial updates in myeloma
Key updates on CAR-T therapy for ALL
The Myeloma Sessions: post-COMY 2021 myeloma patients session
EHA 2021: MRD in myeloma
Latest updates on CAR-T therapy for CLL
The Myeloma Sessions: post-COMy 2021 roundtable
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
MDS Session: Women in Science
Key updates on CAR-T & cellular therapy for AML
The MDS Sessions: highlights from ASH 2020
The Transplant Sessions: ASH 2020 highlights
The Lymphoma Sessions: ASH 2020 highlights
Latest updates in Hodgkin lymphoma from ISHL HL 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The Post-EBMT for Trainees VJSessions
Post-ASH Amyloidosis Session from VJHemOnc
The Post EBMT VJSessions from VJHemOnc
Post-EBMT Highlights in Acute Myeloid Leukemia
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.